Top news of the week: 14.04.2020.

Health care, Dot-com bubble, Severe acute respiratory syndrome, Musculoskeletal disorders, Biotechnology, Health

Startups

On Apr 8, 2020
@big4bio shared
RT @LifeSciVC: Booming VC-Backed Biopharma: Strong Market Despite Pandemic. First quarter of 2020 was the largest quarter for U.S. biopharma venture funding ever. https://t.co/mVhLQu2T53 https://t.co/WuQNQEyvsO
Open

Booming VC-Backed Biopharma: Strong Market Despite Pandemic

Booming VC-Backed Biopharma: Strong Market Despite Pandemic

Venture capital is a long investment cycle business, and never before has that been so clear as now in the face of the ongoing COVID pandemic. Even with the unprecedented public equity ...

On Apr 9, 2020
@IAmBiotech shared
[email protected] says #coronavirus drug could enter testing by fall https://t.co/rmenZ7R2W9
Open

Pfizer says coronavirus drug could enter testing by fall

Pfizer says coronavirus drug could enter testing by fall

Pfizer intends to start human tests of a potential coronavirus therapy as soon as August or September, three months sooner than it had thought possible.

On Apr 10, 2020
@IAmBiotech shared
#Biotech startups expand efforts to combat #COVID19 https://t.co/bhi85cF0Hl https://t.co/r0P3EFtC0b
Open

Biotech Startups Expand Efforts to Combat Covid-19

Biotech Startups Expand Efforts to Combat Covid-19

Warren, N.J.-based Celularity Inc. seeks to enroll 84 patients in a clinical trial of a cell therapy, CYNK-001, that could reduce the amount of virus found in patients with Covid-19, the ...

On Apr 10, 2020
@MALifeSciences shared
RT @labcentral: Coming soon: our 2nd webinar on Innovation and Biotech in the time of COVID-19. Join us Tuesday, April 14 at 1:30 PM for "Advice for Start-Ups Facing Uncertainty". How can entrepreneurs continue to develop opportunities? To be discussed and more! Register: https://t.co/09Hq4KsvmP https://t.co/f8eLDZM8in
Open

Innovation and Biotech in the Time of COVID-19: Advice for Startups

Innovation and Biotech in the Time of COVID-19: Advice for Startups

Join LabCentral on Tuesday, April 14th for the second of a three-part series focused on innovation and biotech in the time of COVID-19.

On Apr 9, 2020
@FlagshipPioneer shared
RT @AndrewE_Dunn: "Anybody who continues to try to thrive and hope to God that they survive in the process is not going to do enough to ensure that survival is assured," Flagship's Noubar Afeyan told me. His advice for small biotechs to get through this crisis: https://t.co/EwgcIao4Dq
Open
On Apr 10, 2020
@IAmBiotech shared
Via @NYTimes: More #coronavirus vaccines and treatments move toward human trials https://t.co/vE2EvnQV28
Open

More Coronavirus Vaccine Efforts Move Toward Human Trials

More Coronavirus Vaccine Efforts Move Toward Human Trials

Just three months after the start of the coronavirus pandemic, several biotech companies have shown promising vaccine programs and are beginning trials.

On Apr 13, 2020
@nytimesbusiness shared
Biogen employees unwittingly spread the coronavirus from Massachusetts to Indiana, Tennessee and North Carolina https://t.co/EtNGvf7Xe8
Open

How a Premier U.S. Drug Company Became a Virus ‘Super Spreader’

How a Premier U.S. Drug Company Became a Virus ‘Super Spreader’

Biogen employees unwittingly spread the coronavirus from Massachusetts to Indiana, Tennessee and North Carolina.

On Apr 8, 2020
@BiotechWorld shared
Keros upsizes IPO, raising $96M for blood and musculoskeletal trials https://t.co/5sVlgWBJlw https://t.co/jFrKDpJZUC
Open

Keros upsizes IPO, raising $96M for blood and musculoskeletal trials

Keros upsizes IPO, raising $96M for blood and musculoskeletal trials

Keros Therapeutics has braved a turbulent market to pull off an IPO, hitting the top end of its price range and selling 20% more shares than originally planned. The upsized IPO gives Keros ...